Boston Scientific Co. (NYSE:BSX – Get Free Report) CEO Michael F. Mahoney sold 113,355 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $53.91, for a total value of $6,110,968.05. Following the completion of the sale, the chief executive officer now owns 1,498,922 shares of the company’s stock, valued at $80,806,885.02. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Boston Scientific Price Performance
NYSE BSX opened at $53.42 on Wednesday. Boston Scientific Co. has a 12 month low of $37.74 and a 12 month high of $54.99. The firm has a market capitalization of $78.22 billion, a PE ratio of 89.03, a P/E/G ratio of 2.11 and a beta of 0.78. The company’s 50 day simple moving average is $52.25 and its 200 day simple moving average is $51.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.29 and a quick ratio of 0.80.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.04. The company had revenue of $3.60 billion for the quarter, compared to analysts’ expectations of $3.50 billion. Boston Scientific had a return on equity of 15.16% and a net margin of 6.81%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the firm earned $0.44 EPS. As a group, equities research analysts forecast that Boston Scientific Co. will post 1.99 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on BSX
Institutional Investors Weigh In On Boston Scientific
Institutional investors and hedge funds have recently bought and sold shares of the business. Fiduciary Alliance LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $25,000. Householder Group Estate & Retirement Specialist LLC bought a new position in shares of Boston Scientific in the first quarter valued at $26,000. Asset Dedication LLC lifted its position in shares of Boston Scientific by 109.5% during the 1st quarter. Asset Dedication LLC now owns 551 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 288 shares during the last quarter. BDO Wealth Advisors LLC boosted its stake in shares of Boston Scientific by 209.4% during the 2nd quarter. BDO Wealth Advisors LLC now owns 594 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 402 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in shares of Boston Scientific in the 1st quarter worth $32,000. 89.11% of the stock is owned by institutional investors and hedge funds.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Stories
- Five stocks we like better than Boston Scientific
- How to Calculate Stock Profit
- Ray Dalio’s Move into 3 Stocks, All Betting on One Thing
- Conference Calls and Individual Investors
- Airbnb Joins the S&P 500, Time to Buy In?
- How to Evaluate a Stock Before Buying
- Does Dell Technologies Blowout Quarter Mean a New Demand Cycle?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
